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PRÉCIS
Worldwide research and development expenditures on an HIV vaccine are
approximately one billion U.S. dollars per year. While vaccines have been
highly successful in preventing diseases, the most promising clinical trials to
date suggest that a vaccine for HIV will be only moderately efficacious in
preventing infection and will require multiple doses. We explore the ethical
and policy implications of a moderately effective HIV vaccine. We examine
anticipated costs, benefits, risks, and dissemination challenges. We conclude
that a twofold approach of (1) using existing treatments to reduce viral loads
and prevent transmission and (2) pursuing a cure for HIV may be more costeffective and beneficial in the long run than developing a vaccine.

I. INTRODUCTION
More than three decades have passed since the initial clinical observation
of Acquired Immunodeficiency Syndrome (AIDS) cases in 1981 and since the
discovery of the etiologic agent, Human Immunodeficiency Virus (HIV) in
1983.1 Since these discoveries, public, philanthropic, and commercial entities
have invested in research to discover how to prevent, treat, and cure HIV and
AIDS. Through this research, great advances have been made, most
importantly, the discovery of Combination Antiretroviral Therapy (cART),
which has converted AIDS from a nearly universally fatal disease to a chronic
condition.2 Significant research has been made in prevention as well,
including: antiretroviral treatments to prevent transmission,3 pre-exposure and
post-exposure prophylaxis,4 education and prevention strategies,5 and methods
to prevent the maternal-fetal transmission of HIV.6

1. Françoise Barré-Sinoussi et al., Past, Present and Future: 30 Years of HIV Research, 11
NAT. REVS. MICROBIOLOGY 877, 877 (2013).
2. Id. at 879.
3. Myron S. Cohen et al., Prevention of HIV-1 Infection with Early Antiretroviral Therapy,
365 NEW ENG. J. MED. 493, 494 (2011).
4. See Kenneth H. Mayer, Antiretroviral Chemoprophylaxis: State of Evidence and the
Research Agenda, 59 CLINICAL INFECTIOUS DISEASES S47, S47 (Supp. 2014); Dawn K. Smith et
al., Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other
Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S.
Department of Health And Human Services, MORBIDITY & MORTALITY WKLY. REP.,
RECOMMENDATIONS & REPS., Jan 21, 2005, at 1, 3.
5. See Helen B. Chin et al., The Effectiveness of Group-Based Comprehensive RiskReduction and Abstinence Education Interventions to Prevent or Reduce the Risk of Adolescent
Pregnancy, Human Immunodeficiency Virus, and Sexually Transmitted Infections: Two
Systematic Reviews for the Guide to Community Preventive Services, 42 AM. J. PREV. MED. 272,
274 (2012).
6. See Kevin M. De Cock et al., Prevention of Mother-to-Child HIV Transmission in
Resource-Poor Countries: Translating Research Into Policy and Practice, 283 JAMA 1175
(2000).
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None of these advances, however, promise to eradicate the virus from the
population. To the extent that we have successfully eradicated other viruses—
such as polio and measles—it has been through the development and
dissemination of vaccines. In general, such vaccines have been safe, effective,
and cost-saving.7 Consider the vaccine for the Hepatitis B virus (HBV), a
sometimes fatal virus that is transmitted in many of the same ways as HIV
(through sexual intercourse and intravenous (IV) drug use).8 Five vaccines now
exist.9 Each is approximately ninety-four percent effective in preventing
chronic carriage of all known subtypes or variants of the virus.10 After
vaccinating more than 100 million people in the U.S., no serious side effects
have been reported.11 Only two to four doses are required in infancy to provide
immunity throughout the first decade of life.12 With little public controversy,
the vaccine has been mandated for infants in forty-seven states,13 and since
1990, rates of acute Hepatitis have dropped eight-two percent.14
Publicly promoting such a vaccine through coverage by the Affordable
Care Act (ACA)15 and state mandatory vaccination laws arguably meets the
five “justificatory conditions” proposed by James Childress and colleagues for
justifying a public health policy, even when it clashes with some competing
values:
(1) Effectiveness: The policy must be expected to achieve its aim (e.g.,
significantly reducing rates of HBV-infection was realistic through mandated
vaccinations).

7. F. E. Andre et al., Vaccination Greatly Reduces Disease, Disability, Death and Inequity
Worldwide, 86 BULL. WORLD HEALTH ORG. 140–42 (2008).
8. CTRS. FOR DISEASE CONTROL & PREVENTION, EPIDEMIOLOGY AND PREVENTION OF
VACCINE-PREVENTABLE DISEASES 120 (William Atkinson et al. eds., 12th ed. 2012) [hereinafter
VACCINE-PREVENTABLE DISEASES].
9. Hepatitis B, NAT’L VACCINE INFO. CTR, http://www.nvic.org/Vaccines-and-Diseases/
Hepatitis-B.aspx (last visited Mar. 9, 2015); VACCINE-PREVENTABLE DISEASES, supra note 8, at
124, xii.
10. VACCINE-PREVENTABLE DISEASES, supra note 8, at 134.
11. Hepatitis B FAQs for the Public, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/hepatitis/B/bFAQ.htm, (last updated Mar. 6, 2015).
12. See VACCINE-PREVENTABLE DISEASES, supra note 8, at 126; Hepatitis B FAQs for
Health Professionals, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/hepati
tis/HBV/HBVfaq.htm (last updated Mar. 6, 2015).
13. State Mandates on Immunization and Vaccine—Preventable Diseases: Hepatitis B,
IMMUNIZATION ACTION COALITION, http://www.immunize.org/laws/hepb.asp (last updated Jan.
15, 2015) (listing Alabama, Montana and South Dakota as the three states who do not have a
Hepatitis B childhood vaccination mandate.).
14. Incidence of Acute Hepatitis B—United States, 1990-2002, 52 MORBIDITY &
MORTALITY WKLY. REP.1245, 1253 (2004).
15. See The Affordable Care Act and Immunization, DEP’T OF HEALTH & HUMAN SERVS.,
http://www.hhs.gov/healthcare/facts/factsheets/2010/09/The-Affordable-Care-Act-and-Immuniza
tion.html (last updated Jan. 20, 2012).
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(2) Proportionality: The good achieved must balance favorably against the
infringement of other values (e.g., reducing chronic HBV-infection rates by
eighty-two percent helps to justify some degree of infringement on parental
authority or diversion of funding for other health needs).
(3) Necessity: The infringement of a value such as autonomy must be
necessary to achieve a public health aim such as herd immunity to Hepatitis B
(e.g., current high rates of Hepatitis B vaccination arguably would have been
difficult to achieve through a voluntary program).
(4) Least infringement: The infringement of other values should be
minimized (e.g., children are not forcibly vaccinated, rather it is a condition for
access to some school systems).
(5) Public justification: Policy makers should be transparent and explain
the reasons for the policy (e.g., the Centers for Disease Control and Prevention
(CDC) has developed an extensive website that provides information about
16
Hepatitis B and the vaccination program).

The National Institute of Allergy and Infectious Diseases (NIAID) states
that, “[f]inding a safe, effective, and durable HIV vaccine remains a top
priority for NIAID.”17 Several HIV vaccines have advanced to human clinical
trials in and have demonstrated some level of success in reducing infection
rates.18 However, as we indicate in this paper, it appears that initial vaccines
for HIV will be less effective, will require more doses to achieve immunity,
will offer immunity for shorter periods of time, and accordingly, will be more
expensive and difficult to administer than the Hepatitis B vaccine (or measles,
polio, Human Papillomavirus (HPV), or any other commonly mandated
vaccine.)19 The medical, economic, logistical, and political realities of HIV
vaccines are extremely complex. This complexity generates a host of ethical
and policy questions.
This paper proceeds by identifying these questions, elucidating why they
arise, and explaining their significance. As a general rule, we do not venture to
answer these questions. In some instances, this is because further data is
needed before anyone can answer the questions; in other instances, it is
because the questions pertain to matters of policy that should be resolved
through processes of public education, engagement, deliberation, and decisionmaking. Simply outlining ethical and policy issues surrounding an HIV
16. James F. Childress et al., Public Health Ethics: Mapping the Terrain, 30 J. L. MED. &
ETHICS 170, 173 (2002).
17. HIV Vaccine Research, NAT’L INST. OF ALLERGY & INFECTIOUS DISEASES (last updated
Feb. 19, 2014), http://www.niaid.nih.gov/topics/hivaids/research/vaccines/Pages/default.aspx.
18. See, e.g., An HIV Vaccine: The World’s Best Long-Term Hope for Ending AIDS, FRED
HUTCHINSON CANCER RES. CTR., http://www.hvtn.org/en.html (last visited Mar. 25, 2015);
Mattia Bonsignori et al., An Autoreactive Antibody From an SLE/HIV-1 Individual Broadly
Neutralizes HIV-1, 124 J. CLINICAL INVESTIGATION 1835, 1835 (2014).
19. See infra Part III.A.
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vaccine may sound like a modest goal, but we believe it is crucial at this
juncture.
Perhaps no other disease has generated so many passionate stakeholder
groups, including:
 Those at highest risk within the U.S., including men who have sex with
men (MSM) and IV drug users (IVDU), who have often been
marginalized in society;
 Those at highest risk internationally, including heterosexual men and
women in many African nations;
 Children who are orphaned by AIDS;
 Government officials who seek to fight HIV/AIDS while wrestling with
budget constraints;
 Health care providers who struggle with limits imposed by the scarcity
of health resources;
 Pharmaceutical companies that could advance their mission and generate
profit with a vaccine discovery, but might also lose revenue from
medications used to treat a chronic condition; and,
 Public health experts who have had mixed success in behavior-based
prevention efforts.
In such a context, deliberations about HIV vaccines may be highly
politicized and contaminated by rhetoric that could unduly influence decisionmakers if they are not well informed. This article is intended to provide
stakeholders and policymakers with an overview of the complex issues
surrounding an HIV vaccine and a basic understanding of why the complexity
will resist easy solutions.
While HIV has affected many nations more severely than the U.S. (e.g., in
sub-Saharan Africa almost one in twenty adults is infected),20 we focus our
analysis on the U.S. context to examine more effectively, questions
surrounding approval from the Food and Drug Administration (FDA), patent
law, social dynamics, and other questions that are nation-specific.
In Part II, we provide a description of HIV—or more accurately, the types,
groups, and genetic subtypes of retroviruses in the HIV-family, the nature of
HIV transmission, and the demographics of the disease burden. In Part III, we
examine why it has been so difficult to develop an HIV vaccine, and we
explore what kind of efficacy we can reasonably expect from the first
generation of HIV vaccines. In Part IV, we try to anticipate the risks of an HIV
vaccine, including adverse events, unintended changes in behavior, and social
harms. In Part V, we discuss factors that will drive up the costs of an HIV
vaccine and discuss some of the ethical issues presented by costs. In Part VI,
we try to anticipate controversies surrounding the distribution of an HIV
20. HIV/AIDS Fact Sheet N°360, WORLD HEALTH ORG., http://www.who.int/mediacentre/
factsheets/fs360/en/ (last updated Nov. 2014).
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vaccine. We conclude by applying the five justificatory conditions for public
health policies and practices to an HIV vaccine. In the process of doing so, we
hope not only to raise awareness of how challenging HIV vaccines are to
public policy, but also to identify significant knowledge and process gaps that
should be met prior to evaluating an HIV licensing application.
II. THE PROBLEM OF HIV
HIV was first recognized in June of 1981, when the CDC reported five
cases of pneumonia caused by Pneumocystis jirovecii (at that time referred to
as Pneumocystis carinii) in MSM living in Los Angeles.21 These first cases
were thought to be a new disease confined to the population of MSM, but it
soon expanded to heterosexual men and women and IVDUs throughout much
of the world.22 In 1983, a retrovirus (now known as HIV) was isolated from a
patient with this syndrome in France.23 Within that same year, the FDA
approved a commercial test to detect the virus.24
HIV manifests as an acute infection with symptoms appearing two to six
weeks after laboratory seroconversion.25 Symptoms include maculopapular
rash, fever, myalgia, arthralgia, headache, diarrhea, sore throat, or neurological
manifestations.26 Extremely high levels of the virus are present during acute
infection and are likely a significant source of transmission.27 Antibodies to
HIV normally develop within two months,28 although there have been sporadic
reports of delayed seroconversion.29 For the most part, these antibodies are not
able to control or prevent ongoing viral replication.30
According to CDC criteria, AIDS is diagnosed when the immune system
of a person infected with HIV becomes severely compromised (as measured by
the CD4 cell count) and/or the person becomes ill with an opportunistic
infection.31 Without HIV therapy, the individual becomes increasingly
21. First Report of AIDS, 50 MORBIDITY & MORTALITY WKLY. REP. 429, 429 (2001).
22. Barré-Sinoussi et al., supra note 1, at 877; Michael H. Merson et al., The History and
Challenge of HIV Prevention, 372 LANCET 475, 475 (2008).
23. Barré-Sinoussi et al., supra note 1, at 877.
24. Id.
25. Andrew R. Moss & Peter Bacchetti, Natural History of HIV Infection, 3 AIDS 55, 55
(1989).
26. Id.
27. Penny Lewthwaite & Ed Wilkins, Natural History of HIV/AIDS, 37 MED. 333, 333
(2009).
28. Id. at 334.
29. Moss & Bacchetti, supra note 25, at 55; see also S. Skidmore et al., A Case Study of
Delayed HIV-1 Seroconversion Highlights the Need for Combo Assays, 20 INT’L J. STD & AIDS
205, 205 (2009).
30. Moss & Bacchetti, supra note 25, at 55.
31. About HIV/AIDS, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
hiv/basics/whatishiv.html (last updated Jan. 16, 2015).
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susceptible to opportunistic infections,32 and diseases caused by these
pathogens are “AIDS-defining conditions,” and include herpes viruses
(Kaposi’s sarcoma, lymphoma, and cytomegalovirus), Pneumocystis jerovicii,
invasive fungal infections, and mycobacterial infections such as TB.33 In the
absence of treatment, AIDS develops eight to ten years after initial infection.34
When the first cases of AIDS presented to clinicians, the only thing they could
do was treat the opportunistic infections with marginal success. HIV became
the leading cause of death in twenty-five to forty-four year olds by 1993.35
This trend peaked in 1996 before rapidly declining and, by 2010, HIV was the
seventh leading cause of death in that age group.36 Today, with advances in
cART, HIV has been transformed from a once fatal to a now manageable
chronic disease.37 While current cART suppresses the virus, it does not
eradicate it, and lifelong treatment is still required,38 which carries both
financial and physical costs. A few cases of HIV eradication (cure) or
suppression without requiring cART (functional cure) have been reported,39
but have generally been in unusual circumstances, such as extremely early
treatment,40 or a bone marrow transplant by a donor genetically incapable of
HIV infection,41 and rebound has been reported in several of these cases.42

32. Id.
33. Revised Surveillance Case Definition for HIV infection Among Adults, Adolescents, and
Children Aged < 18 Months and for HIV Infection and AIDS Among Children Aged 18 Months to
< 13 Years – United States, 2008, 57 MORBIDITY & MORTALITY WKLY REP 1, 9 (2008)
(outlining the AIDS-Defining Conditions in Appendix A).
34. Jair C. Leao et al., Oral Complications of HIV Disease, 64 CLINICS 459, 460 (2009).
35. Update: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years –
United States 1994, 45 MORBIDITY & MORTALITY WKLY REP. 121, 121 (1996).
36. KAISER FAMILY FOUND., THE HIV/AIDS EPIDEMIC IN THE UNITED STATES 1 (2014)
(citing to the CDC’s Mortality Slide Show Through 2010); CTRS. FOR DISEASE CONTROL &
PREVENTION, MORTALITY SLIDE SERIES 20 (2013), available at http://www.cdc.gov/hiv/pdf/sta
tistics_surveillance_HIV_mortality.pdf.
37. Barré-Sinoussi et al., supra note 1, at 879.
38. Id. at 880.
39. See generally Asier Sáez-Cirión et al., Post-Treatment HIV-1 Controllers with a LongTerm Virological Remission After the Interruption of Early Initiated Antiretroviral Therapy
ANRS VISCONTI Study, 9 PLOS PATHOGENE 1, 1 (2013).
40. Id.; Ari Bitnun et al., Early Initiation of Combination Antiretroviral Therapy in HIV-1 –
Infected Newborns Can Achieve Sustainted Virologic Suppression With Low Frequency of CD4+
T Cells Carrying HIV in Peripheral Blood, 59 CLINICAL INFECTIOUS DISEASES 1012, 1014
(2014).
41. Gero Hütter et al., Long-Term Control of HIV by CCR5 Delta32/Delta 32 Stem-Cell
Transplantation, 360 NEW ENG. J. MED. 692, 696-97 (2009).
42. Press Release, Nat’l Inst. Of Allergy & Infectious Disease, “‘Mississippi Baby’ Now
Has Detectable HIV, Researchers Find (Jul. 10, 2014), available at http://www.niaid.nih.gov/
news/newsreleases/2014/Pages/MississippiBabyHIV.aspx.
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Viral Mechanisms of HIV

HIV-1 and HIV-2 are members of the lentivirus family of retroviruses.
Cross-species infection from primates to humans probably occurred by blood
contamination through hunting. HIV-1 and HIV-2 both cause AIDS, but HIV-2
is both less virulent and less prevalent.43 HIV-1 causes over ninety-eight
percent of AIDS cases worldwide.44 “HIV-1 can be further subdivided into
different groups (M, O, [N, and P]) and subtypes.”45 For example, HIV-1
group M has nine identified genetic subtypes (A-K, excluding E and I).46 Each
genetic subtype is traditionally associated with specific geographical areas. For
example, subtype A is associated with West Africa, and subtype B is most
prevalent in Europe, the Americas, Japan, Thailand, and Australia.47 “Globally,
subtype C accounts for half of all strains.”48 It is likely that a vaccine will
target only certain subtypes, complicating vaccine distribution.
Retroviruses such as HIV have an RNA-genome and require reverse
transcription to complete the viral life cycle.49 This process is inaccurate, and
the viral genome is capable of mutating each base pair in its genome up to
100,000 times per day, generating quasi-species of genetically-related viruses
soon after infection.50
B.

Transmission Demographics

HIV is present in blood, semen, and other bodily fluids and is transmitted
mainly through sexual intercourse.51 Globally, the primary modes of
transmission are heterosexual contact and mother to child (vertical
transmission), but considerable variation exists between and within countries.52

43. Lewthwaite & Wilkins, supra note 27, at 333; Andrew M.L. Lever, HIV: The Virus, 37
MED. 313, 313 (2009).
44. Lever, supra note 43, at 313.
45. Lewthwaite & Wilkins, supra note 27, at 333; Ana Vallari et al., Confirmation of
Putative HIV-1 Group P in Cameroon, 85 J. VIROLOGY 1403, 1403 (2011).
46. Abraham J. Kandathil et al., Molecular Epidemiology of HIV, 121 INDIAN J. MED. RES.
333, 334 (2005).
47. Id. at 337; Lewthwaite & Wilkins, supra note 27, at 333.
48. Lewthwaite & Wilkins, supra note 27, at 333.
49. Lever, supra note 43, at 313.
50. Ricardo Sobhie Diaz et al., Divergence of HIV-1 Quasispecies in an Epidemiologic
Cluster, 11 AIDS 415, 415 (1997); Alan S. Perelson et al., HIV-1 Dynamics in Vivo: Virion
Clearance Rate, Infected Cell Life-Span, and Viral Generation Time, 271 SCIENCE 1582, 1583
(1996).
51. Lewthwaite & Wilkins, supra note 27, at 333.
52. Id.
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The primary modes of transmission in the U.S. for example, are anal sex and
IV-drug use.53
We focus on demographic data provided in the CDC’s HIV Surveillance
Report, 2012.54 Approximately 880,400 (or three in one thousand) individuals
are known to be living with HIV throughout the U.S.55 The CDC estimates that
approximately 200,000 additional individuals are infected, but are unaware of
their infection.56 There are approximately 50,000 new diagnoses of HIV and
20,000 deaths from HIV-related illnesses each year.57 The distribution of HIV
varies significantly by race in the U.S. with Black/African American (forty-six
percent), White (twenty-eight percent), and Hispanic/Latino (twenty-one
percent).58 Among males, the primary modes of transmission are male-to-male
sexual contact (eighty-one percent), followed by heterosexual contact (ten
percent), and injection drug use (five percent).59 Among women, transmission
occurs primarily through heterosexual contact (eighty-seven percent) and
injection drug use (twelve percent).60 Children under thirteen comprise half of
one percent of all cases, most involving peri-natal transmission (fifty-seven
percent).61
III. THE DIFFICULTY OF DEVELOPING AN HIV VACCINE
Vaccines have led to the eradication of smallpox and near eradication of
polio, and protect humans from measles, rubella, tetanus, mumps, influenza,
and Hepatitis B.62 Wayne Kopf provides a succinct explanation of different
ways vaccines work:
Viral vaccines protect against disease by priming the immune system before
pathogen exposure. This generates antibody responses that can prevent
infection [as well as] cellular responses that target and eliminate virus-infected
cells. Virus-specific neutralizing antibodies bind to proteins on the surface of

53. CTRS. FOR DISEASE CONTROL & PREVENTION, TODAY’S HIV/AIDS EPIDEMIC 3 (2014),
available at http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/TodaysEpidemic508.pdf.
54. See generally Ctrs. for Disease Control & Prevention, Diagnoses of HIV Infection in the
United States and Dependent Areas, 2012, HIV SURVEILLANCE REP., Nov. 2014 [hereinafter
SURVEILLANCE REP.].
55. Id. at 9.
56. Ctrs for Disease Control & Prevention, Monitoring Selected National Prevention and
Care Objectives Using HIV Surveillance Data—United States and 6 Dependent Areas 2012, HIV
SURVEILLANCE REP., Nov. 2014, at 1, 10 (Supp. Nov. 2014).
57. SURVEILLANCE REP., supra note 54, at 19, 40.
58. Id. at 18.
59. Id.
60. Id. at 19.
61. Id.
62. Ivan Stratov & Stephen Kent, Towards an HIV Vaccine, 32 AUSTRALASIAN SCIENCE 31,
31 (2011).
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viral particles and stop them from infecting host cells. Neutralizing antibodies
can also bring about the destruction of virus-infected cells, via cellular effector
mechanisms. Where natural virus infection elicits robust neutralizing-antibody
responses, vaccines have been developed by using attenuated versions of the
live virus (such as for measles, mumps, and rubella); inactivation (for polio);
and virus surface protein subunits or virus-like particles (for hepatitis B and
63
human papilloma virus).

Why, after more than three decades, do we not have an effective vaccine
against HIV? Most importantly, currently available vaccines exist for
pathogens to which many people develop protective immunity (i.e., patients
who recover from the illness are protected against re-infection). The vaccine
mimics this known protective response. Very few HIV-infected patients are
able to control the infection and there are no patients identified who have
cleared the infection completely. Those patients who do control the virus
appear to do so by generating an effective cytotoxic T cell-response,64 which is
quite different from the antibody-response generated by most licensed
vaccines.
Technical barriers exist as well. Because of safety concerns, an effective
HIV vaccine would be unlikely to consist of attenuated, actively replicating
(live) HIV, due to possible reversion to full virulence. Virus protein subunit
vaccines or killed whole virus vaccines, have been problematic due to the
extensive variability generated by the sloppiness of the viral polymerase,
creating not a single target, but a swarm of related targets.65 This variability
allows “the virus to escape both pharmacological attack and immunological
defenses.”66
Finally, scientists have never before attempted to develop a vaccine against
a retrovirus like HIV. Retroviruses, by integrating their genome into ours, are
able to hide completely from immune surveillance within quiescent
lymphocytes.67 This means that any vaccine has a small window of opportunity
in which to prevent infection and would have to be extremely effective,
repelling all attempts by HIV to attach to and infect host cells. HIV produces
viral proteins that actively interfere with the anti-HIV immune response in both
infected and uninfected cells.68 For all these reasons, an effective HIV vaccine
will likely require uniquely different strategies from currently licensed
vaccines, which will likely increase cost and complicate distribution methods.
63. Wayne C. Koff, Accelerating HIV Vaccine Development, 464 NATURE 161, 161 (2010).
64. Stratov & Kent, supra note 62, at 32.
65. Dennis R. Burton et al., A Blueprint for HIV Vaccine Discovery, 12 CELL HOST &
MICROBE 396, 396-97 (2012).
66. Lever, supra note 43, at 316; see also Travis C. Porco & Sally M. Blower, Designing
HIV Vaccination Policies: Subtypes and Cross-Immunity, 28 INTERFACES 167, 167-68 (1998).
67. Lever, supra note 43, at 315.
68. Id.
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Multiple vaccine strategies have been tried since the discovery that HIV
causes AIDS. The first Phase I HIV vaccine trial took place in 1987.69
According to the International AIDS Vaccine Initiative’s database, two
hundred and twelve Phase I trials, nineteen Phase I/II trials, and thirty-four
Phase II trials have taken place as of January 2015.70 These studies have
provided both promising results and serious setbacks, most notably the early
stopping of a Merck STEP vaccine study in 2003, after the realization that the
vaccine increased the risk of HIV acquisition in some participants.71 Only three
Phase III studies of HIV vaccines have been done, involving two AIDSVAX
types (B/B in Canada, the Netherlands, and Puerto Rico; and B/E in
Thailand)72 and a combination study of AIDSVAX B/E with ALVAC, also
known as RV144.73 The most promising of these trials was RV144, a six-year
trial conducted in Thailand with the sponsorship of the U.S. Army HIV
Research Program and NIAID.74 The trial involved 16,400 people.75 While the
vaccine had an initial efficacy of approximately seventy percent, this declined
to about thirty percent within three and a half years.76 Although U.S. public
health officials have never approved a vaccine with such low efficacy, the
RV144 trial is the first vaccine to demonstrate any significant efficacy against
HIV, and has renewed hopes for a marketable vaccine.77
A.

Anticipated Effectiveness of a Vaccine

In evaluating the efficacy of a vaccine, several endpoints are used: (1)
susceptibility to establishment of infection upon exposure, (2) progression of

69. José Esparza, An HIV Vaccine: How and When, 79 BULL. WORLD HEALTH ORG. 1133,
1135 (2001).
70. See IAVIReport: Clinical Trials Database, INT’L AIDS VACCINE INITIATIVE,
http://www.iavireport.org/Trials-Database/Pages/default.aspx (last updated February 10, 2015)
[hereinafter Clinical Trials Database]. Summaries of all of the trials references in this paragraph
can be accessed in their Clinical Trials Database.
71. See Questions & Answers: HVTN 502 & HVTN 503 HIV Vaccine Clinical Trials, NAT’L
INST. OF ALLERGIES & INFECTIOUS DISEASES, http://www.niaid.nih.gov/news/qa/pages/step_
qa.aspx (last updated Feb. 6, 2008); The STEP Study, NAT’L AIDS MANUAL, http://www.aids
map.com/The-STEP-study/page/1065651/ (last visited Mar. 9, 2015).
72. Clinical Trials Database, supra note 70.
73. Id.
74. See RV 144 Trial, U.S. MILITARY HIV RES. PROG., http://www.hivresearch.org/research.
php?ServiceID=13, (last visited March 9, 2015); see also Phase III Trial-Thailand, U.S.
MILITARY HIV RES. PROG. (2010), http://www.hivresearch.org/media/pnc/9/media.439.pdf.
75. Supachai Rerks-Ngarm et al., Vaccination With ALVAC and AIDSVAX To Prevent HIV-1
Infection in Thailand, 361 NEW ENGL. J. OF MED. 2209, 2210 (2009).
76. Kyeen M. Andersson et al., The Potential Impact of an HIV Vaccine with Rapidly
Waning Protection on the Epidemic in Southern Africa: Examining the RV144 Trial Results, 29
VACCINE 6107, 6108 (2011).
77. Clinical Trials Database, supra note 70, at Special Report Thai Trial Results.
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the disease among those who are already infected, and (3) infectiousness or the
risk of transmission to others.
Most currently available vaccines are highly efficacious in reducing
susceptibility to viral infection. For example, both vaccines currently licensed
to prevent HPV—Gardasil and Cervarix—are nearly one hundred percent
efficacious in preventing diseases caused by exposure to high-risk strains of
HPV (HPV sixteen and eighteen),78 which together account for seventy percent
of all cervical cancers as well as many cancers of the vagina and vulva.79 The
HBV vaccine is ninety-four percent effective in preventing susceptibility to
chronic carriage of the HBV.80
In contrast to HPV and HBV vaccines, early HIV vaccines are likely to be
low to moderate in reducing susceptibility, but may slow disease progression
and lower infectiousness.81 Whereas efficacy in reducing susceptibility is the
primary aim of vaccine development, control of the HIV epidemic could be
achieved if a vaccine reduced the rate of transmission to less than one per
infected individual.82
In contrast to efficacy, which is determined under experimental conditions,
effectiveness is the ability of a vaccine to produce outcomes of interest in the
“real world” and is affected by factors such as patient compliance, cost,
behavioral changes, and supply.83 However, when evaluating new drugs and
biologics for safety and effectiveness, the FDA typically equates effectiveness
with efficacy in clinical trials conducted under conditions that are often times
more controlled than most patient care settings.84
As we proceed to evaluate the risks and benefits of an HIV vaccine, we
propose a hypothetical scenario. No HIV vaccine to date has exceeded an
initial efficacy of seventy percent or sustained an efficacy above forty
percent.85 We will optimistically, and somewhat arbitrarily, assume for the

78. Barbara Romanowski, Long Term Protection Against Cervical Infection with the Human
Papillomavirus: Review of Currently Available Vaccines, 7 HUMAN VACCINES 161, 161-62
(2011).
79. Id. at 164-65.
80. Hilton Whittle et al., Observational Study of Vaccine Efficacy 14 Years After Trial of
Hepatitis B Vaccination in Gambian Children, 325 BMJ 1, 2 (2002).
81. Public Health Considerations for the Use of a First Generation HIV Vaccine, 17 AIDS
W1, W2 (2003).
82. Id. at W3.
83. See INS’T OF MED., GUIDELINES FOR CLINICAL PRACTICE: FROM DEVELOPMENT TO
USE 61, 66-68 (Marilyn J. Field & Kathleen N. Lohr eds.,1992); see generally Colin Depp &
Barry D. Lebowitz, Clinical Trials: Bridging the Gap Between Efficacy and Effectiveness, 19
INT’L REV. PSYCHIATRY 531 (2007).
84. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: PROVIDING CLINICAL EVIDENCE OF
EFFECTIVENESS FOR HUMAN DRUG AND BIOLOGICAL PRODUCTS 1 n. 2 (1998).
85. See Elisa F. Long & Douglas K. Owens, The Cost-Effectiveness of a Modestly Effective
HIV Vaccine in the United States, 29 VACCINE 6113, 6113 (2010) (where vaccine efficacy was
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sake of argument that a vaccine is sixty percent efficacious in preventing HIV
upon exposure. However, it has a significantly lower rate of effectiveness
because it requires recipients to obtain four shots over a six-month period as
well as an annual booster shot.86
B.

Anticipating the Risks of an HIV Vaccine

Proactive management of the risks of an HIV vaccine will be a necessary
component of any successful HIV vaccine approval process and subsequent
campaign.
1. What adverse events might an HIV vaccine cause?
HIV vaccine clinical trials have reported only mild to moderate vaccine
reactions. Adverse events observed during HIV vaccine trials have been
similar to other vaccines: pain and swelling localized at the injection site,
fevers of mild to moderate severity, chills, diarrhea, aches and pains, nausea,
headache, dizziness, and fatigue.87 Standard strategies for managing safety
risks from vaccines include providing information on risks, adverse event
reporting, long-term monitoring programs, and mechanisms of legal redress for
injury.88 However, existing vaccine safety surveillance programs, such as the
Vaccine Adverse Event Reporting System (VAERS), may be insufficient for
adequately monitoring HIV vaccine safety, given the characteristics of likely
recipient populations and the relative homogeneity of trial subjects. As
VAERS relies on self-reporting and reporting by medical professionals,89 the

highest at approximately seventy percent in the first year, but rapidly declined over time, showing
a thirty-one percent vaccine efficacy overall).
86. See Kristen Jill Kresge, Special Report: Thai Trial Results, Results from RV144 Send
Scientists in Search of Clues, IAVI REPORT, http://www.iavireport.org/Special-Features/Pages/
SpecialReportThaiTrialResults.aspx (last visited Mar. 8, 2015) (discussing the RV 144 HIV
vaccine trial that used a prime-boost regimen consisting of six shots—four primers and two
boosters—given over the course of six months, which one sponsor of the trial stated was “not
exactly a deployable regimen”).
87. Andrew T. Catanzaro et al., Phase 1 Safety and Immunogenicity Evaluation of a
Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant
Adenovirus Vector, 194 J. INFECTIOUS DISEASES 1638, 1640, 1643 (2006); Elizabeth. L. Cooney
et al., Safety of and Immunological Response to a Recombinant Vaccinia Virus Vaccine
Expressing HIV Envelope Glycoprotein, 337 LANCET 567, 569 (1991); Frances H. Priddy et al.,
Safety and Immunogenicity of a Replication- Incompetent Adenovirus Type 5 HIV-1 Clade B
gag/pol/nef Vaccine in Healthy Adults, 46 CLINICAL INFECTIOUS DISEASES 1769, 1772 (2008).
88. See generally Vaccine Adverse Event Reporting System, U.S. DEP’T HEALTH & HUMAN
SERVS., https://vaers.hhs.gov/index (last visited Mar. 26, 2015).
89. Weigong Zhou et al., Surveillance for Safety After Immunization: Vaccine Adverse Event
Reporting System (VAERS) – United States, 1991-2001, in CTR. FOR DISEASE CONTROL &
PREVENTION, SURVEILLANCE FOR SAFETY AFTER IMMUNIZATION: VACCINE ADVERSE EVENT
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adverse events experienced in high-risk communities with limited health care
access may go unreported. Moreover, it is unclear whether our standard
processes for compensating those injured by vaccination will work with an
HIV vaccine. Injuries attributed to most of the vaccines administered in the
U.S., including the HPV and HBV vaccines, are compensated through the
National Vaccine Injury Compensation Program (VICP).90 The VICP allows
individuals claiming an injury caused by a covered vaccine to petition the U.S.
Federal Claims Court for compensation, including coverage of the medical
expenses incurred as a result of the injury.91 However, the VICP only covers
vaccines that are routinely administered to children.92 Thus, an HIV vaccine
would be added to the list of VICP covered vaccines only if it is recommended
for routine administration to children. Moreover, a new mechanism for legal
redress of HIV vaccine injuries will likely need to be developed.
Additional concerns regarding vaccine safety could be addressed via FDA
Risk Evaluation and Mitigation Strategies (REMS). A product of the Food and
Drug Administration Amendments Act of 2007 (FDAAA),93 REMS are
required risk management plans that extend beyond typical labeling
requirements to ensure the benefits of a particular treatment outweigh its
risks.94 The FDA is not required to order REMS for a particular biologic, but
rather considers several factors in making that determination: the size of the
targeted population, seriousness of the disease, expected benefit and duration
of the treatment, and the seriousness of potential side effects.95 Given the
deadly and widespread nature of HIV, it seems the FDA could very well
consider requiring REMS for an HIV vaccine. REMS must include a timetable
for submissions of REMS-assessments and may also include a medication
guide, a communication plan, elements to assure safe use, and an
implementation system.96 Medication guides are written in non-technical

REPORTING SYSTEM (VAERS) 2 (2003), http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5201
a1.htm.
90. See U.S. DEP’T HEALTH & HUMAN SERVS., WHAT YOU NEED TO KNOW ABOUT THE
NATIONAL VACCINE INJURY COMPENSATION PROGRAM (VICP) 1, 1-2 (2011). The VICP was
created through the National Childhood Vaccine Injury Act of 1986. Id. at 1. See also 42 U.S.C. §
300AA-1 (2012).
91. Katherine M. Cook & Geoffrey Evans, The National Vaccine Injury Compensation
Program, 127 PEDIATRICS S74, S75 (2011).
92. Id. at S75.
93. See generally Food and Drug Administration Safety and Innovation Act, Pub. L. No.
110–85, 121 Stat. 823 (2007).
94. FOOD & DRUG ADMIN., A BRIEF OVERVIEW OF RISK EVALUATION AND MITIGATION
STRATEGIES (REMS) 1-2, available at http://www.fda.gov/downloads/AboutFDA/Transparency/
Basics/UCM328784.pdf (last accessed Mar. 22, 2015) [hereinafter RISK EVALUATION &
MITIGATION].
95. Id. at 6.
96. Id. at 7.
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language and presented in an easily accessible format providing information
such as possible side effects, overdose precautions and instructions, and a brief
description of the product.97 Communication plans attempt to increase
understanding of a drug’s or biologic’s risks through letters to health care
providers, circulating information contained in the REMS to various
professional societies, and encouraging methods to alleviate risks.98 Finally,
Elements to Assure Safe Use (ETASU) establish the requirements that health
care professionals must meet before administering, prescribing, or continuing a
particular treatment.99 The related implementation system dictates the steps a
drug or biologic sponsor will take to ensure that ETASU are executed and
followed.100 Examples of ETASU include possessing specific training or
certifications, or subjecting patients to monitoring.101 As a product of some or
all of these parts, REMS can help identify and address concerns with vaccine
safety.
2. How will an HIV vaccine affect risky sexual behavior?
As HIV prevention technologies diminish perceptions of risk, risk-taking
behavior may increase, a phenomenon referred to as “risk compensation.”102 If
individuals perceive a significant protective effect of an HIV vaccine, they
may be more willing to engage in risky behaviors. Absent a fully protective
vaccine and optimal uptake, increases in risky behavior, such as IVDU and
unprotected sex, may increase the incidence of HIV transmission. For example,
a decrease in the use of condoms, which provide between eighty and ninety
percent protection against HIV when regularly used, may increase the overall
incidence of HIV.103 Risk compensation thus has the potential to offset the
population-level benefit of an HIV vaccine. In addition to diminishing the net
benefit of an HIV vaccine, risk compensation may increase the incidence of
other sexually transmitted infections, unwanted pregnancy, and IV use.
Mathematical modeling suggests the extent to which risk compensation
may offset the benefits of a vaccination program. However, mathematical
modeling has been very limited.

97. Id. at 8.
98. Id. at 10.
99. RISK EVALUATION & MITIGATION, supra note 94, at 12.
100. Id. at 16.
101. Id. at 13.
102. Lisa A. Eaton & Seth C. Kalichman, Risk Compensation in HIV Prevention:
Implications for Vaccines, Microbicides, and Other Biomedical HIV Prevention Technologies, 4
CURRENT HIV/AIDS REP. 165, 170 (2007).
103. Markus J. Steiner & Willard Cates Jr., Condoms and Sexually-Transmitted Infections,
354 NEW ENG. J. MED. 2642, 2642 (2006).
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Andersson et al. used prevalence data for South Africa to model the
relationship between vaccine efficacy and risk compensation.104 Published in
2007, the study concluded that a twenty-five percent decrease in condom use
following a vaccination program, with a forty percent effective vaccine, would
decrease HIV prevalence from twenty percent to fifteen percent (as compared
to a decrease from twenty percent to thirteen percent without a decrease in
condom use).105 The study assumed that the vaccine would have one hundred
percent take (elicit some immunological response in all recipients), provide ten
years of protection, and would be administered to seventy-five percent of the
population over seventeen years of age.106 However, given a twenty percent
effective vaccine and a fifty percent decrease in condom use, a vaccination
program would increase the prevalence of HIV.107 As the model used the much
higher prevalence rates found in South Africa (approximately eleven and a half
percent for men; twenty percent for women),108 these findings do not provide
an indication of how risk compensation might impact the benefits of a
vaccination program in the U.S., which has very low prevalence rates.
Long et al.’s discussion of the potential benefits and costs of an HIV
vaccine considered how an increase in sexual partners would impact the
benefits of vaccination.109 The authors concluded that if vaccinated individuals
had twenty-five percent more sexual partners than unvaccinated individuals, a
vaccine of at least sixty-five percent efficacy would provide a net benefit due
to population mixing (HIV-infected individuals would be more likely to have
sex with a vaccinated individual).110 The authors did not account for other
changes in risk behavior.
Blower et al.’s study of HIV eradication in San Francisco, which found
that a modest increase in risk behavior of ten percent would offset any decrease
in incidence offered by a fifty percent effective vaccine, offers the most insight
into risk compensation following a vaccination program in the U.S.111

104. Kyeen M. Andersson et al., Predicting the Impact of a Partially Effective HIV Vaccine
and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and MiddleIncome Countries: A South African Example, 46 J. ACQUIRED IMMUNE DEFICIENCY
SYNDROMES, 78, 79 (2007).
105. Id. at 81.
106. Id. at 79-80.
107. Id. at 81.
108. Id. at 79.
109. Long & Owens, supra note 85, at 6116.
110. Id. at 6116-17.
111. S. M. Blower & A.R. McLean, Prophylactic Vaccines, Risk Behavior Change, and the
Probability of Eradicating HIV in San Francisco, 265 SCIENCE 1451, 1453 (1994); Peter A.
Newman et al., HIV Risk and Prevention in a Post-Vaccine Context, 22 VACCINE 1954, 1954
(2004).
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Subsequent work by Rajaraman et al. emphasizes the role of the
transmission network in modulating the effectiveness of a vaccine
intervention.112 In sexually transmitted diseases such as HIV, transmission
requires risky behavior by both the infected patient and the uninfected
partner—a two-sided behavior. This contrasts with diseases, such as influenza,
that are primarily transmitted through the risky behavior of individuals. An
individual’s risky behavior, including travel and contact with crowds, increases
the risk of transmission to multiple others—a one-sided behavior.113 For onesided behaviors, high vaccination coverage mitigates increased risky behavior.
For two-sided interactions, vaccination must be combined with programs to
decrease risky behavior, as modeling of this behavior reveals that unintended
outcomes occur at high levels of vaccination. Additionally, this modeling
reveals that interventions that target highly connected individuals (as is
common among HIV transmission networks) can sometimes be worse than
random interventions.114
Studies of anticipated behavioral changes have predicted a modest increase
in risky behavior following vaccination with an HIV vaccine.115 In interviews
conducted with 1,164 high-risk individuals in Los Angeles County, Newman et
al. found modest anticipated increases in high-risk behaviors.116 After
receiving a hypothetical HIV vaccine of fifty percent efficacy, six percent of
respondents said they would use condoms less for vaginal sex, seven percent
said they would use condoms less for anal sex, and approximately seven and a
half percent anticipated an increase in sexual partners.117 However, anticipated
risk compensation increased dramatically when subjects were presented with a
high-efficacy HIV vaccine.118 Similarly, twenty-two percent of respondents in
a South African study believed that they would use condoms less frequently
after receiving a thirty percent effective vaccine.119 The conclusions supported
by these studies are limited by the reliance on individual reporting of
112. Rajmohan Rajaraman et al., Network Effects of Risk Behavior Change Following
Prophylactic Interventions. 8 PLOS ONE, Aug. 2013, at 1, 12.
113. Id. at 2.
114. Id. at 6.
115. Richard A. Crosby & David R. Holtgrave, Will Sexual Risk Behaviour Increase After
Being Vaccinated for AIDS?, 17 INT’L J. STD & AIDS 180, 182 (2006); Peter A. Newman et al.,
Preventive HIV Vaccine Acceptability and Behavioral Risk Compensation among a Random
Sample of High- Risk Adults in Los Angeles (LA VOICES), 44 HEALTH SERVS RES. 2167, 2175
(2009) [hereinafter Preventive HIV Vaccine]; Kyeen M. Andersson, et al., Anticipated Changes in
Sexual Risk Behaviour Following Vaccination with a Low-Efficacy HIV Vaccine: Survey Results
from a South African Township, 23 INT’L J. STD & AIDS 636, 738 (2012) [hereinafter
Anticipated Changes].
116. Preventive HIV Vaccine, supra note 115, at 2171, 2175.
117. Id. at 2174.
118. Id.
119. Anticipated Changes, supra note 115, at 737-38.
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anticipated changes in behavior, which may overestimate or underestimate
actual changes in behavior.
In contrast, studies of the behavioral changes of HIV vaccine trial
participants suggest that risk compensation will not increase significantly in
response to a vaccine. A recent study of participants in a South African
vaccine efficacy trial did not find evidence of risk compensation.120 The
majority of trial participants maintained baseline risk behaviors during the
course of the study. At six months, approximately thirty percent of men and
thirty-six percent of women stated that they had changed from having
unprotected sex to having protected sex.121 These findings are consistent with
the observation that many participants in pre-exposure prophylaxis (PrEP)
trials engaged in safer sexual practices after enrollment.122
The decrease in risky sexual behaviors following enrollment in
preventative trials may be attributed to the provision of risk counseling
services.123 Preventative trials are designed to reduce potential harms and
generally include a mechanism to minimize risk compensation. In addition to
risk counseling, education regarding the efficacy of vaccines is crucial to
minimizing risk compensation. The public is likely to overestimate the efficacy
profile of an approved and marketed HIV vaccine. Interviews with high-risk
individuals revealed that participants generally presumed that an approved
vaccine would be one hundred percent efficacious.124 Moreover, an individual
who has an all-or-nothing understanding of efficacy may increase risky
behavior after HIV exposure, considering failure to contract the disease as
evidence of a completely protective effect.125
The extent to which informational initiatives may combat the problem of
risk compensation is unclear. Participants who have reported engaging in risky
sexual behavior during an HIV vaccine trial accurately recounted the trial’s
directions to practice safe sex,126 suggesting that risk compensation is not
solely attributable to information deficits.

120. G. E. Gray et al., Does Participation in an HIV Vaccine Efficacy Trial Affect Risk
Behaviour in South Africa?, 31 VACCINE 2089, 2092 (2013).
121. Id. at 2093.
122. Robert M. Grant et al., Preexposure Chemoprophylaxis for HIV Prevention in Men Who
Have Sex with Men, 363 NEW ENG. J. MED. 2587, 2598 (2010); Jared M. Baeten et al.,
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women, 367 NEW. ENG.
J. MED. 399, 408-09 (2012).
123. Gray et al., supra note 120, at 2094.
124. Preventive HIV Vaccine, supra note 115, at 1960.
125. Id.
126. Margaret A. Chesney et al., Risk Behavior for HIV Infection in Participants in
Preventive HIV Vaccine Rrials: A Cautionary Note, 16 J. ACQUIRED IMMUNE DEFICIENCY
SYNDROMES & HUMAN RETROVIROLOGY, 226, 227-28 (1997).

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2015]

ANTICIPATING HIV VACCINES

243

Lessons may be learned from PrEP, a drug intervention that provides fortyfour percent additional protection against HIV infection.127 The CDC released
guidance for PrEP in May 2014, recognizing that HIV preventative programs
should be implemented in conjunction with other preventative services.
According to the CDC, these include “educating patients about their
medications; helping them anticipate and manage side effects; helping them
establish dosing routines that mesh with their work and social schedules;
providing reminder systems and tools; addressing financial, substance abuse,
or mental health needs that may impede adherence; and facilitating social
support.”128 The report acknowledges that current findings regarding that
antiretroviral medication adherence may be only partially applicable to
adherence enhancement among PrEP-users.129
It is worth noting that despite good evidence for efficacy in multiple trials,
there has been low uptake of PrEP thus far,130 indicating that there is still
considerable confusion both among providers and patients about who should
be prescribed PrEP, for how long, and how costs should be covered. However,
physicians that work with the MSM community have said that a preventive
measure that is available with more intermittent dosing might see more interest
and uptake.131 Similar features might be present in a moderate-efficacy, highcost HIV vaccine.
3. What social harms might an HIV vaccine cause for recipients?
The social response to HIV/AIDS has historically been defined by social
stigma and the threat of discrimination.132 An HIV vaccine may exacerbate
existing stigmas and present new opportunities for discrimination, especially if
the vaccine is disseminated to narrow populations already at risk of stigma and
discrimination (such as the MSM community and racial minorities.)133 For

127. Douglas Krakower & Kenneth H. Mayer, Promising Prevention Approaches: Tenofovir
Gel and Prophylactic Use of Antiretroviral Medications, 8 CURRENT HIV/AIDS REPS. 241, 242
(2011).
128. DAWN K. SMITH ET AL., PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV
INFECTION IN THE UNITED STATES – 2014 CLINICAL PRACTICE GUIDELINE 1, 44 (2014).
129. Id.
130. Stacy Lu, Preventing HIV, One Pill at a Time, MONITOR ON PSYCHOLOGY, Jan. 2015, at
40, 41.
131. Mark Mascolini, Who’s Prepared to Make PrEP work?, 17 RES. INITIATIVE
TREATMENT ACTION 1, 16 (2012).
132. See WORLD HEALTH ORG., GLOBAL HIV/AIDS RESPONSE: EPIDEMIC UPDATE AND
HEALTH SECTOR PROGRESS TOWARDS UNIVERSAL ACCESS PROGRESS REPORT 2011 at 1, 4, 76,
101 (2011), available at http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf?ua
=1.
133. See generally Peter Newman et al., What Can HIV Vaccine Trials Teach Us About
Future HIV Vaccine Dissemination?, 26 VACCINE 2528, 2532-34 (2008) [hereinafter Future
Vaccine Dissemination].
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early recipients, the motivator for uptake may be perceived as engagement in
high-risk behavior,134 potentially alienating the recipient from his or her
community. Dissemination strategies must accordingly account for inadvertent
privacy invasions through inference.135 For instance, mobile HIV vaccination
sites may permit the inference that those entering or leaving are interested in
receiving the vaccine because they engage in high-risk behaviors.136 Similarly,
overutilization of needle exchange and HIV testing clinics as sources of
vaccine dissemination may function to discourage uptake by associating
recipients with high-risk behavior.
In inducing an antibody-response, an HIV vaccine also induces
seropositivity and thus, HIV vaccine recipients will test seropositive for
HIV.137 Although false positives may be distinguished from actual viral
seropositivity depending on the nature of the vaccine and the assay used,
vaccine-induced seropositivity complicates the interpretation of HIV testing
results, increasing the likelihood that an individual may be considered HIV
positive.138 False seropositives mistaken for actual HIV infection may have
implications for travel, immigration, and insurance discrimination.139
C. Anticipated Costs
At least two factors generate concern that the costs of an HIV vaccine
could be too high to make global distribution feasible. First, Pharmaceutical
Research and Manufacturers of America (PhRMA) estimates that research and
development (R&D) of new drugs and therapeutics typically takes ten to
fifteen years, costs an average of $1.2 billion, and only twenty percent of
marketed drugs “return revenues that match or exceed R&D costs.”140 The
total investment in R&D costs worldwide for an HIV vaccine from 2009-2013
has been estimated at $4.27 billion (U.S.D.), which is sixty-eight percent of all
investment in HIV/AIDS-R&D.141 In contrast, investment in prevention
134. Id. at 2532.
135. Id. at 2534.
136. Malika Roman Isler et al., Acceptability of a Mobile Health Unit for Rural HIV Clinical
Trial Enrollment and Participation, 16 AIDS & BEHAVIOR 1895, 1897-98 (2012).
137. Cristine J. Cooper et al., Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected
HIV Vaccine Recipients, 304 JAMA 275, 275, 279 (2010).
138. Id. at 280, 282.
139. Future Vaccine Dissemination, supra note 133, at 2532.
140. PHARMACEUTICAL RES. & MANUFACTURERS OF AM., 2013 INDUSTRY PROFILE:
BIOPHARMACEUTICAL RESEARCH INDUSTRY ii (2013) [hereinafter BIOPHARMACEUTICAL
RESEARCH], available at http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%2020
13.pdf.
141. HIV VACCINES & MICROBICIDES RESOURCE TRACKING WORKING GRP., HIV
PREVENTION RESEARCH & DEVELOPMENT INVESTMENT IN 2013: IN A CHANGING GLOBAL
DEVELOPMENT, ECONOMIC AND HUMAN RIGHTS LANDSCAPE 3 (July 2014), available at
http://hivresourcetracking.org/sites/default/files/RTWG2014.pdf.
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treatment (ninety-six percent efficacious in preventing transmission) has been
$0.24 billion (U.S.D.), or two percent of investment totals in the same time
period.142
A second potential financial barrier is the goal of generating significant
income from sales to recoup R&D costs and generate a profit for investors,
which might be both significant and protected by patent law. Simply defined, a
patent is an exclusive property right granted to an entity for a particular
invention so long as the invention is new or involving an inventive step; it is a
right to exclude others from producing, using, or selling the patented
invention.143 Patent law also grants patent holders with the authority to
determine price setting within certain limits.144 Since patent holders are
generally able to control price setting, subject to constraints on
monopolization, the financial barriers to access can vary considerably.145 It is
also important to note that any one vaccine contains several distinct parts or
processes (e.g., antigen, adjuvant, and the delivery device), most of which are
individually patentable.146 This feature of vaccination can make avoiding
infringement difficult, as manufacturers must consider not only the vaccine
itself, but the very basics of its composition.147
One potential way of overcoming the obstacles to vaccine access in the
U.S. is through compulsory licensing via antitrust laws and lawsuits for patent
misuse.148 U.S. antitrust laws permit actions against a patent holder if the
alleging party can demonstrate that a particular patent has been wrongfully
broadened in a way that negatively affects either competition or the integrity of
the patent system.149 If antitrust laws are breached, that patent can be deemed
unenforceable or under certain circumstances the patent holder may be
compelled to grant a third party a license to engage in the manufacture of the
patented product.150 Another potential way to increase access in the U.S. is
through the process of price negotiation. Since major health maintenance
organizations (HMO) and pharmacy benefit managers cover sixty-seven
percent of U.S. patients, this represents a particularly attractive mechanism for

142. Id.
143. Christopher Garrison, Intellectual Property Rights and Vaccines in Developing Countries
8 (April 13, 2004) (Background Paper for World Health Organization Workshop).
144. Jerome H. Reichman, Compulsory Licensing of Patented Inventions: Comparing United
States Law and Practice With Options Under the TRIPS Agreement 2-3 (June 13-16, 2006)
(Paper Presented at the Association of American Law Schools midyear conference).
145. Id.
146. Hillary Greene, Patent Pooling Behind the Veil of Uncertainty: Antitrust, Competition
Policy, and the Vaccine Industry, 90 B.U. L. REV. 1398, 1400 (2010).
147. Id.
148. See generally Reichman, supra note 144.
149. Id. at 3.
150. See id.
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driving down costs.151 Patent-pooling, a form of voluntary licensing, is another
option licensors have to help increase manufacturing efficiency and reduce the
costs of producing vaccinations.152 Patent-pooling is the process of joint
licensors creating a pool of their respective patents so that one license can
convey the entirety of the pool to a potential licensee.153 However, overusing
voluntary licensing can have a negative impact on competition, as royalty
payments typically do not lower prices to the same extent as general market
competition. Lastly, the most common remedy for antitrust violations in the
U.S. is the invocation of the government-use provision, 28 U.S.C. § 1498. This
provision grants the government or its contractors the authority to use a
patented product or process without license so long as the patent holder is paid
“reasonable and entire compensation.”154 Determining an appropriate price
would likely require consideration of the patented vaccine’s status under the
Drug Price Competition and Patent Term Restoration Act (also known as the
Hatch-Waxman Act), a major piece of legislation governing the approval and
marketing of generic drugs.155
A vaccine like the one proposed in this piece may also qualify for FDAgranted market exclusivity for up to seven years if certain statutory
requirements are met.156 By granting exclusivity, the FDA promotes innovation
by rewarding manufacturers who expend the resources necessary to deliver
new, effective products with exclusivity over the market, and thus, increase
revenue. Moreover, this statutory exclusivity can exist without a concurrently
running patent.157 This is another potential avenue available to help drive R&D
while avoiding some of the hindrances of intellectual property and patent law.
From an international standpoint, there are additional mechanisms within
the Agreement on Trade Related Aspects of Intellectual Property (TRIPS) that
serve to increase global access to important vaccines on a global level.158

151. John H. Barton & Ezekiel J. Emanuel, The Patents-Based Pharmaceutical Development
Process: Rationale, Problems, and Potential Reforms, 294 JAMA 2075, 2078 (2005).
152. Greene, supra note 146, at 1424.
153. Id. at 1415.
154. Reichman, supra note 144, at 5.
155. Robin J. Strongin, Hatch-Waxman, Generics, and Patents: Balancing Prescription Drug
Innovation, Competition, and Affordability, NAT’L HEALTH POLICY FORUM, June 21, 2001, 1 at
8-9, available at http://www.nhpf.org/library/background-papers/BP_HatchWaxman_6-02.pdf
(highlighting the provisions of Hatch-Waxman which covered drug price competition and the
Abbreviated New Drug Application (ANDA) process for generics and patent term restoration).
156. See generally 21 C.F.R. § 314.108 (2014).
157. Frequently Asked Questions About Drugs, FOOD & DRUG ADMIN., http://www.fda.gov/
AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm082690.htm (last
visited Mar. 6, 2015).
158. See generally UNAIDS, WHO, & UNDP, POLICY BRIEF: USING TRIPS FLEXIBILITIES
TO IMPROVE ACCESS TO HIV TREATMENT (2015), available at http://www.who.int/phi/phi_trips
_policybrief_en.pdf.
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TRIPS is the most comprehensive multilateral agreement on intellectual
property. In addition to voluntary licensing and compulsory licensing
mentioned above, TRIPS also includes two other measures: tiered pricing and
bulk purchasing.159 Tiered pricing is the practice of setting prices based on the
developmental status of the purchasing country.160 This approach, however,
can be negatively affected by scheduled divergence, an event that hinders
access because manufacturers cannot keep up with a vaccine demand that
differs considerably between nations, especially when manufacturers rely on
sales within developed countries to cover the majority of their costs.161 Lastly,
TRIPS also provides for bulk purchasing and advanced purchasing
commitments.162 The bulk purchasing mechanism operates on the general
principle that a large volume of goods can be bought at a cheaper price per
unit,163 a principle especially appropriate for vaccines, considering their
widespread demand. Similarly, advanced purchase commitments (i.e., bulk
purchasing done prior to development or widespread manufacturing) provide
added incentives for developers and manufacturers to generate vaccines by
assuring a willing purchaser.164 While patents may burden access to an
approved HIV vaccine, there are existing mechanisms for overcoming these
impediments.
Even if the barriers of R&D costs and patent law are overcome and a
reasonable price per dose is established, an HIV vaccine may still be cost
prohibitive. Again for the sake of argument, we will stipulate a hypothetical
cost per dose for each vaccine of $250 based on the analysis of Elisa Long and
Douglas Owens.165 Based on our hypothesized dosing schedule of four doses
in year one and an annual booster, the total cost is $1,000 in year one and the
ten-year cost is $3,250 per person. If recipients do not follow up with the
annual boosters, vaccine efficacy will decline rapidly.166
Such costs may be prohibitive to widespread dissemination, particularly at
a global level, where poverty is more prevalent and transmission patterns are
not limited to easily identifiable high-risk groups. In fact, if an HIV vaccine is
only moderately effective and some of its effectiveness is offset by behavioral
risk adjustments, then the costs of an HIV vaccine do not supplant, but rather
are added to the costs of other preventive measures and treatment.

159. Garrison, supra note 143, at 3.
160. Barton & Emanuel, supra note 151, at 2078.
161. Garrison, supra note 143, at 23.
162. Id. at 3; see also Ernst R. Berndt & John A. Hurvitz, Vaccine Advance-Purchase
Agreements For Low-Income Countries: Practical Issues, 24 HEALTH AFF. 653, 653 (2005).
163. Garrison, supra note 143, at 23.
164. Berndt & Hurvitz, supra note 162, at 654.
165. Long & Owens, supra note 85, at 6117.
166. Id. at 6115.
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D. Anticipated Distribution Controversies
Distribution of an HIV vaccine will be affected by economic factors,
logistics, the efficacy of the vaccine, and social reactions within different
nations and communities.
1. Should vaccine distribution target high-risk populations?
For reasons of cost-effectiveness, a low to moderate efficacy HIV vaccine
(less than eighty percent efficacy) will likely be recommended only for highrisk populations.167 A low to moderate efficacy vaccine will also carry the
same problems as the Bacille Calmette-Guérin (BCG) vaccination to prevent
TB. For example, although it may be modestly effective, use of the BCG
vaccine complicates health care services by interfering with the most
commonly used testing modalities for asymptomatic (latent) TB.168 Similarly, a
modestly effective HIV vaccine may be problematic, as it would result in
positive HIV tests (i.e., ELISA and Western blot) for patients at highest risk
for acquiring HIV. This would require the use of a more expensive test (the
HIV viral load) for screening this population.
It is unclear whether high-risk populations will spontaneously seek
vaccination if the benefits are only modest. For example, even with good
efficacy, when patients comply with a daily regime of PrEP, uptake has been
very slow within the MSM community.169 It is likely that widespread
vaccination within high-risk populations will require targeted vaccine
campaigns, which may include social marketing, educational outreach
programs, strategically located delivery centers, and financial incentivizing—
all of which add to the costs of a vaccine campaign.170
While these strategies do not directly encroach upon the autonomy of the
individual target recipient, they may compound social pressure and stigma.
Social marketing, which exploits the desire for social acceptance, may

167. Jose Esparza et al., Estimation of “Needs” and “Probable Uptake” for HIV/AIDS
Preventive Vaccines Based on Possible Policies and Likely Acceptance (A WHO/UNAIDS/IAVI
Study), 21 VACCINE 2032, 2034 (2003).
168. The standard method for testing TB is the Mantoux tuberculin skin test (TST), which
injects tuberculin purified protein derivative (PPD) into the inner surface of the forearm. CTRS.
FOR DISEASE CONTROL & PREVENTION, TB ELIMINATION: TUBERCULIN SKIN TEST 1 (2011),
available at http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf. Although
responses are inconsistent, studies have shown that prior BCG vaccination increases the risk of
receiving a false-positive result under a TST. Id.; Kathleen Rowland et al., How Should We
Manage a Patient With a Positive PPD and Prior BCG Vaccination, 55 J. FAMILY PRACTICE 718,
719 (2006).
169. Mascolini, supra note 131.
170. Jeroen Luyten et al., Vaccination Policy and Ethical Challenges Posed by Herd
Immunity, Suboptimal Uptake and Subgroup Targeting, 4 PUB. HEALTH ETHICS 280, 282, 284
(2011).
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exaggerate perceptions of homogeneous characteristics (for example, the belief
that all members of the MSM community practice unsafe sex) and exacerbate
social anxieties among members of the target population.171 Educational
outreach programs and local delivery centers may inadvertently facilitate
perceptions that HIV is isolated to socially deviant communities. Financial
incentives, when offered only to those in high-risk populations, may encourage
perceptions of social dependency. Efforts to target vaccine uptake must
balance public health goals with respect for target populations.
The risk of alienating at-risk populations may be managed by including
members of at-risk populations in the development of targeting campaigns. To
minimize the risk of stigma and discrimination, targeting policies should also
focus as much as possible on relevant individual factors, such as identifying
populations with high prevalence of HIV in their sexual network, and
individuals who present with recurrent sexually transmitted diseases (STD).172
A focus on individually relevant factors rather than group generalizations will
decrease opportunities for stigma. For example, targeting men who have
unsafe sex with men, rather than the entire MSM community, recognizes the
diversity of the MSM community.173 However, the tailoring of targeted
vaccine policy to individual characteristics requires greater scrutiny, poses a
risk of invading individual privacy, and would require physicians to take more
complete sexual histories to identify individuals at risk.174
The success of targeted vaccination efforts will be limited by inequalities
in health care access, as dissemination programs will need to rely on the
existing health care infrastructure.175 Thus, eradication of HIV will likely
depend not only on the successful development of preventive technologies, but
also investment in expanding the health care infrastructure to disadvantaged
communities. For example, although African American and Latino
communities have historically exhibited suboptimal uptake of vaccines and
HIV treatment, poor uptake likely reflects access issues.176
The Belmont Report, which provides ethical principles to guide research
funded by the U.S. government, additionally raises justice-based concerns
about targeting at-risk populations in the U.S. for distribution of a vaccine, if
the clinical trials leading to the development and approval of a vaccine

171. Alison Thompson, Human Papilloma Virus, Vaccination and Social Justice: An Analysis
of a Canadian School-Based Vaccine Program, 6 PUB. HEALTH ETHICS 11, 16 (2013).
172. See, e.g., Luyten et al., supra note 170, at 285.
173. Id.
174. Id. at 286.
175. Esparza et al., supra note 167, at 2037.
176. Future Vaccine Dissemination, supra note 133, at 2529.
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recruited participants from developing nations.177 For example, individuals
who assume the risks of clinical trials should belong to the same group of
individuals who are likely to benefit from the trials.178 That is, the context of
HIV vaccine research may require that we have a plan for affordable
distribution of the vaccine within resource-poor nations concomitant with U.S.
distribution. However, this will pose a significant challenge to the market if the
vaccine is approved only for use in high-risk populations because this would
radically restrict the size of the U.S. market, which commonly shoulders the
primary burden in the recovery of R&D costs.179
2. Might the state mandate an HIV vaccine?
The question remains whether an approved HIV vaccine should be
mandated. States have traditionally been charged with making determinations
regarding mandatory vaccination via school attendance requirements as well as
deciding which exemptions should be recognized.180 A state derives its
authority to mandate vaccinations from the police power, a product of the
Tenth Amendment to the U.S. Constitution, which grants states those powers
“not delegated to the United States.”181 In Jacobson v. Massachusetts, the
Supreme Court of the United States held that a Massachusetts law requiring
citizens to undergo vaccination for smallpox was a valid exercise of the police
power.182 The Court held that the law bore a substantial relationship to the
protection of public health and it was reasonable for the state legislature to
invest the Board of Health with the power to determine which diseases threaten
the community’s safety.183 States also have traditionally relied on the parens
patriae (Latin for “parent of the country”) doctrine, the traditional authority for
the state to protect its citizens.184
Since the states’ police power has been widely accepted for decades,
primarily on the basis of public health, general vaccination requirements are

177. NAT’L COMM’N FOR PROT. HUMAN SUBJECTS BIOMEDICAL & BEHAVIORAL RES., THE
BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN
SUBJECTS OF RESEARCH 9-10 (1978).
178. Harold Varmus & David Satcher, Editorial, Ethical Complexities of Conducting
Research in Developing Countries, 337 NEW ENG. J. MED. 1003, 1004-05 (Oct. 1997).
179. Immunization, Vaccines and Biologicals: HIV/AIDS, WORLD HEALTH ORG.,
http://www.who.int/immunization/topics/hiv/en/WHO.INT (last updated Jun. 18, 2008).
180. James G. Hodge, Jr. & Lawrence O. Gostin, School Vaccination Requirements:
Historical, Social, and Legal Perspectives, 90 KY. L.J. 831, 851 (2001-2002).
181. U.S. CONST. amend. X.
182. Jacobson v. Mass., 197 U.S. 11, 35 (1905).
183. BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS AND PROBLEMS 76 (7th
ed. 2013).
184. Allen Craig et al., New Adolescent Vaccines: Legal and Legislative Issues, 35 J.L. MED.
& ETHICS 106, 108 (2007).
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usually legitimate, subject to a few constitutional limits that vaccination laws
must conform to in order to withstand constitutional scrutiny. First, the
legislative measure must serve a public health necessity, which means the
public health powers can only be invoked to combat an avoidable harm.185
Second, the measure must be reasonable, namely it must bear a “real or
substantial relation” to the protection of the public health.186 Third, the
measure must be proportional, meaning the measure’s burden cannot be
excessive or outweigh its anticipated benefit.187 Finally, the public health
measure itself cannot cause harm to its subjects.188 So long as vaccination
mandates conform to the above limitations, they will likely defeat
constitutional challenges.
States will need to keep in mind that just because an HIV vaccine is FDAapproved does not mean that it will necessarily pass these four tests for the use
of police powers. HIV vaccines with low, moderate, and high efficacy need to
be treated differently. While a highly efficacious HIV vaccine could
accomplish a public health benefit if mandated, a low or moderately
efficacious HIV vaccine could very well have the opposite effect.189 Based on
the fact that mandate decisions fall to the state, decisions of whether or not to
mandate HIV vaccination will be geographical in nature and deeply influenced
by a state’s rate of HIV infection.
3. Social Controversy
While the justification for mandating vaccination may be strongest in
regard to diseases that spread by casual contact, there are other vaccinations
commonly mandated even though their associated diseases are not likely to be
spread via casual contact. For example, tetanus and Hepatitis B are unlikely to
be contracted from casual contact, since tetanus is most commonly acquired
through contamination of a cut or wound, and HBV is largely sexuallytransmitted.190 The highly infectious nature of HBV as a blood borne
pathogen191 and the public health need to ensure the safety of the blood supply
have likely also contributed to its inclusion as a mandatory vaccine.

185. Kristin Cook, Note, Ethical and Legal Issues Accompanying Legislation Requiring HPV
Vaccination of Girls, 18 HEALTH MATRIX 211, 221 (2008).
186. Id.
187. Id. at 222.
188. Id.
189. See Esparza et al., supra note 167, at 2034, and accompanying text.
190. Gillian Haber et al., The HPV Vaccine Mandate Controversy, 20 J. PEDIATRIC &
ADOLESCENT GYNECOLOGY 325, 326 (2007).
191. See Hepatitis B Fact Sheet N°204, WORLD HEALTH ORG., http://www.who.int/mediacen
tre/factsheets/fs204/en/ (last updated Mar. 2014).
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Currently, HBV vaccination is mandatory in all states with the exceptions
of Alabama, South Dakota, and Montana.192 It is interesting to contrast the
history and status of the HBV vaccine to the HPV vaccine, which similarly
aims to prevent the spread of a sexually transmitted virus.
Over the past decade there has been notable protest regarding compulsory
HPV vaccination of school-aged children.193 The controversy surrounding
HPV vaccination is focused on both social and scientific grounds. From a
scientific position, critics of mandatory vaccination feel that since the longterm effectiveness of HPV vaccines is not known, it is inappropriate to
mandate vaccination in light of uncertainties concerning risk to the public.194
On the social side, critics of mandatory HPV vaccination focus on the fact that
HPV is not casually contracted, although it is highly infectious, with a
prevalence rate as high as fifty percent in sexually active female adolescents
and young adults.195 These critics maintain that providing vaccinations for
HPV may undermine abstinence-based teachings and that vaccines will offer a
false sense of security that could lead to a decline in safe sex practices.196
Vamos, McDermott, and Daley write:
Childhood immunizations, such as measles, chicken pox, and polio, are
mandatory for school-aged youth and are required because of their highly
contagious nature, especially in settings where people congregate in large
numbers. Therefore, the question is whether there is justification for mandating
parents to vaccinate their children against a sexually transmitted virus, one that
can only be transmitted through sexual behavior that some people view as
197
being irresponsible.

Any effort to widely distribute an HIV vaccine may face similar challenges
within certain sectors of society, which view sexual behavior not merely in
terms of introducing “risk factors,” but also in terms of morality, and
frequently, a traditional sexual morality that condemns sex outside of
heterosexual marriage.
Allowing exceptions to mandatory vaccination has been a means of
addressing social outcry. Forty-eight states (excluding Mississippi and West
Virginia) recognize religious exemptions.198 The level of evidence needed to

192. See supra note 13 and accompanying text.
193. See Haber et al., supra note 190.
194. Cheryl A. Vamos et al., The HPV Vaccine: Framing the Arguments For and Against
Mandatory Vaccination of All Middle School Girls, 78 J. SCH. HEALTH 302, 305 (2008).
195. Jessica A. Kahn et al., Mediators of the Association Between Age of First Sexual
Intercourse and Subsequent Human Papillomavirus Infection, 109 PEDIATRICS 1, 1 (2002).
196. Haber et al., supra note 190, at 327.
197. Vamos et al., supra note 194, at 304 (citation omitted).
198. Kevin M. Malone & Alan R. Hinman, Vaccination Mandates: The Public Health
Initiative and Individual Rights, in LAW IN PUB. HEALTH PRACTICE 262, 273 (Richard A.
Goodman ed., 2nd ed. 2007).
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invoke a religious exemption varies by state. A few states require that the
patient be a member of an organized, recognized, or established religion, while
others grant exemptions only if the beliefs are “genuinely and sincerely held,”
while still others require only a completed form stating opposition.199
Philosophical exemptions are more malleable than their religious counterparts
and are also more commonly invoked. Laws governing these exemptions
typically require little evidence to support objection, many times only requiring
a written statement.200 However, many states treat philosophical exemptions as
an all or nothing affair, requiring one to forego all vaccinations instead of
expressing objections to only specific vaccines.201 Twenty states recognize
some form of philosophical exemptions.202
Exceptions have not, however, always satisfied those who object to
mandating vaccination. Following FDA approval of Gardasil and Cervarix and
the recommendation of the national Advisory Committee on Immunization
Practices (ACIP), state legislatures began drafting HPV vaccination laws.203 At
least forty-two states have introduced HPV vaccination legislation to either
require vaccination or provide funding to educate the public and twenty-five of
these states have enacted such legislation with nearly all legislative measures
focusing on grant-funding to educate the public.204 The road to specifically
mandate HPV vaccinations has proven to be more difficult. Only Virginia and
the District of Columbia currently have laws mandating HPV vaccination for
schooling.205
The 2007 events in Texas provide an illustrative example of challenges to
mandatory vaccine laws covering STDs. In 2007, Texas Governor Rick Perry,
believing immediate action was necessary, bypassed the state legislature and

199. Alicia Novak, The Religious and Philosophical Exemptions to State Compelled
Vaccination: Constitutional and Other Challenges, 7 U. PA. J. CONST. L. 1101, 1107-1108
(2005).
200. Id. at 1109.
201. Id.
202. Arizona, Arkansas, California, Colorado, Idaho, Louisiana, Maine, Michigan,
Minnesota, Missouri, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Utah,
Vermont, Washington, and Wisconsin recognize philosophical exemptions. States With Religious
and Philosophical Exemptions From School Immunization Requirements, NAT’L CONF. OF STATE
LEGISLATURES, http://www.ncsl.org/research/health/school-immunization-exemption-state-laws
.aspx (last updated March 3, 2015).
203. See KAISER FAMILY FOUND., THE HPV VACCINE: ACCESS AND USE IN THE U.S. 13
(Feb. 2015), available at http://files.kff.org/attachment/fact-sheet-the-hpv-vaccine-access-anduse-in-the-u-s. The FDA approved Gardasil in 2006 and Cervarix in 2009. Id. at 2; see also HPV
Vaccine Polices, NAT’L CONF. OF STATE LEGISLATURES, http://www.ncsl.org/research/health/
hpv-vaccine-state-legislation-and-statutes.aspx (last visited March 6, 2015) [hereinafter HPV
Vaccine Policies].
204. HPV Vaccine Policies, supra note 203.
205. Id.
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issued an executive order mandating HPV vaccination for girls entering the
sixth grade.206 Almost as quickly as its issuance, the newly signed law
generated substantial public backlash.207 Even though the Texas law, like the
Virginia and District of Columbia laws that are currently in force, allowed
exemptions on medical, religious, and philosophical grounds, concerned
parents still expressed disdain over the perceived erosion of their decisionmaking authority and the hassle of having to formally request exemption.208
Another common challenge confronting HPV vaccine mandates is the parental
fear that vaccinating their children against a STD conveys an implied message
that sexual activity before marriage is permissible.209
Some opponents also argue that mandatory HPV vaccination laws violate
the Equal Protection Clause of the Fourteenth Amendment as such laws
(including both Virginia’s and the District of Columbia’s formulations) require
only girls to be vaccinated despite the FDA’s approval for Gardasil usage
among males.210 Following this extensive public backlash, the Texas
legislature passed a bill nullifying Governor Perry’s executive order, and
Governor Perry subsequently withheld his veto.211 Overall, the arguments
advanced by Perry’s critics are the ones most commonly used to attack similar
vaccination requirements and should be anticipated if an HIV vaccine is
mandated.
Interestingly, mandating vaccination for STDs has also proven
controversial among some groups that support vaccination. For example, the
Catholic Medical Association of the U.S. supports widespread HPV
vaccination and identifies no ethical issues with the vaccine itself, but strongly
opposes mandatory vaccination.212 We expect that if an HIV vaccine is not
recommended for children, and if no attempts are made to mandate the
vaccine, the backlash from religious groups will be significantly less than if the
HIV vaccine was mandated for school-aged children. However, as a
predominant STD, HIV vaccination is likely to be more effective if given prior
to sexual debut.

206. Cook, supra note 185, at 214.
207. Id. at 216-17.
208. Id. at 217.
209. Carrie A. Roll, The Human Papillomavirus: Should It Be Mandatory or Voluntary?, 10
J. HEALTH CARE L. & POL’Y 421, 440 (2007).
210. Christina O. Hud, The Virginia Gardasil Law: A Constitutional Analysis of Mandated
Protection for Schoolchildren Against the Human Papillomavirus, 17 WASH. & LEE. J. CIV. RTS.
& SOC. JUST. 224, 259, 263 (2010).
211. HPV Vaccines Policies, supra note 203.
212. CATHOLIC MED. ASS’N, CATHOLIC MED. ASS’N POSITION PAPER ON HPV
IMMUNIZATION 2-3 (2007), available at http://www.cathmed.org/assets/files/Position%20Paper%
20on%20HPV%20Immunization.pdf.
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Admittedly, mandatory HBV vaccination generated comparably little
controversy and almost no literature, despite the fact that HBV is primarily
sexually-transmitted.213 This may be due in part to the timing of the rollout of
the HBV vaccine. The current vaccine has been used since 1986, a time in
which there was considerable concern for the safety of the blood supply from a
variety of blood borne pathogens, including HBV, HIV, and non-A/non-B
Hepatitis (subsequently identified as Hepatitis C).214 We suspect that the
increased controversy over HPV is due to backlash against vaccination from a
younger population, which never experienced the original devastation caused
by vaccine-preventable diseases, as well as increased influence from political
factions within the U.S. that seek to minimize government intervention into the
lives of citizens. In the current climate, mandating an HIV vaccine would
likely receive a reaction more comparable to the HPV vaccine than to the HBV
vaccine. Additionally, the potential backlash concerning mandatory HIV
vaccination will likely be magnified based on its potential moderate efficacy
profile as compared to the efficacy profiles of the HPV and HBV vaccines.
IV. CONCLUSION
To summarize, based on the most promising clinical trials to date, we
anticipate the first vaccine approved to prevent HIV infection will be only
modestly effective. The type of HIV vaccine that can be expected will not fully
eradicate the disease and, therefore, will not replace the need for ongoing and
improved prevention and treatment efforts. Additionally, a broad vaccination
campaign will be costly given that immunization may require multiple doses in
the first year and annual booster doses. To avoid risk compensation, the
vaccine campaign will require a significant educational component, though it is
not clear that risk compensation is due to informational deficits. Social
resistance to any effort at mandating an HIV vaccine is likely to be strong.
While we have focused on the U.S. context, many of the overarching
concerns—efficacy being limited to specific strains, costs, the burden of
administering multiple doses, risk compensation, and social resistance—
pertain to international settings to an even greater extent than the U.S.

213. See Testimony on Hepatitis B Vaccine Before the H. Comm. on Gov’t Reform, Subcomm.
on Criminal Justice, Drug Policy, and Human Resources, 106th Cong. 1-9 (1999), available at
http://www.hhs.gov/asl/testify/t990518b.html. (testimony from Harold S. Margolis, M.D.Chief,
Hepatitis Branch, Division of Viral & Rickettsial Diseases, U.S. Department of Health & Human
Services).
214. INST. OF MED., HIV AND THE BLOOD SUPPLY: AN ANALYSIS OF CRISIS
DECISIONMAKING, at v (Lauren B. Leveton et al., eds. 1995).
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Suggestions for Justificatory Conditions

We started this paper by presenting the ways that HBV vaccines arguably
satisfy a set of widely recognized justificatory conditions for public health
policies. In contrast to HBV vaccines, the HIV vaccines we anticipate in the
near future do not satisfy the conditions nearly so well. However, in most
cases, we lack the knowledge and clear processes to draw appropriate
conclusions. In what follows, we present the justificatory conditions and offer
suggestions on what would need to occur before a determination is made
regarding whether any particular HIV vaccine should be licensed and approved
for marketing.
1. Effectiveness: The policy must be expected to achieve its aim.
HIV vaccines pose a challenge to this requirement: What level of realworld effectiveness is sufficient? How long must it be sustained? Just as the
FDA has issued Guidance for Industry: Clinical Data Needed to Support the
Licensure of Pandemic Influenza Vaccines,215 it would be helpful if the FDA
issued proactive guidance on the bounds of effectiveness that would be
considered acceptable for licensing an HIV vaccine. Further research is also
needed to provide reliable data on real-world effectiveness as opposed to
efficacy within a controlled trial.
2. Proportionality: The good achieved must balance favorably against
the infringement of other values.
Determinations of proportionality require that the benefits of a vaccine be
weighed against at least two competing considerations: cost and risk
compensation. Between 2009 and 2013, worldwide R&D expenditures on an
HIV vaccine were approximately $4.27 billion.216 Is an HIV vaccine likely to
be cost-effective after considering anticipated real-world effectiveness rates,
costs of implementing the program with boosters, and ongoing needs for
education and treatment? And will the effectiveness rates be high enough to
reduce the disease burden even after taking into account risk compensation? To
answer this question, we urgently need updated mathematical models of the
potential for risk compensation in the context of a vaccination campaign in the
U.S. Proportionality determinations may vary significantly depending on the
population in which the vaccine is approved for use. However, such a
determination might rest largely upon answers to other questions posed
(pertaining to effectiveness, cost, and risk compensation).
215. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CLINICAL DATA NEEDED TO
SUPPORT THE LICENSURE OF PANDEMIC INFLUENZA VACCINES 1 (2014), available at
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guid
ances/Vaccines/ucm074786.htm.
216. See BIOPHARMACEUTICAL RESEARCH, supra note 140, at 32.
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3. Necessity: The infringement of values must be necessary to achieve
the intended public health goal.
One could argue that an HIV vaccine would likely pass this test because
there is no way to develop an HIV vaccine that will not incur costs or run the
risk of some risk compensation. However, one could also argue that it is not
necessary to approve a vaccine with lower than standard rates of efficacy. That
is, if the ultimate goal is to reduce the burden of HIV on the population using
limited funds, one could argue that it makes more sense to focus funding on
other prevention measures, treatment, and R&D aimed not only at vaccines,
but also on treatments or cures.
4. Least infringement: The infringement of other values should be
minimized.
One obvious strategy for least infringement might be to initially approve
an HIV vaccine only for high-risk populations and to approve the vaccine for a
limited period of time, to conduct post-marketing research that might include
cost-effectiveness and the impact on risk compensation.
5. Public justification: Policy makers should be transparent and explain
the reasons for the policy.
More generally, we would interpret this to require inclusion of
stakeholders in deliberations, such as through public comment opportunities or
the creation of review boards that reflect diversity. To satisfy this justificatory
condition, two modifications of FDA processes might be appropriate. First, the
FDA’s approval process requires an overall determination that the anticipated
benefits outweigh risks.217 The scope of this risk-benefit analysis is not clearly
articulated. Can it include the risk of diverting public funding from research on
cures and the provision of treatments? Can it include risks of behavioral
change? Clarifying the scope of the risk-benefit analysis prospectively and
transparently will assist in the evaluation of an HIV licensing application.
Second, the composition of FDA’s review committees might benefit from
expansion to include diverse epidemiologists, policy experts, economists,
ethicists, and representatives of populations most at risk for HIV infection.
Within the FDA, the Center for Biologics Evaluation and Research (CBER)
reviews applications for the approval of vaccines.218 A former director of
CBER, Norman Taylor, states “[m]ost of our staff started in a laboratory or in
217. About FDA: How FDA Evaluates Regulated Products: Drugs, FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last visited March 3,
2015).
218. Vaccine Product Approval Process, FOOD & DRUG ADMIN., http://www.fda.gov/biolog
icsbloodvaccines/developmentapprovalprocess/biologicslicenseapplicationsblaprocess/ucm1330
96.htm (last updated June 18, 2009).
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a clinical setting, a hospital or some other clinical setting, so we have . . . the
ability and the knowledge base to evaluate these products.”219 However, it is
unclear whether standard CBER laboratory and clinical backgrounds and data
analysis are adequate to make the required determination of efficacy when
efficacy is well below previously approved thresholds and diminishes rapidly
in the absence of boosters (or perhaps even with boosters). It is even less clear
that CBER staff have the expertise to conduct the kind of broad risk-benefit
analysis described above. The FDA does have a standing Vaccines and Related
Biological Products Advisory Committee (VRBPAC), which can provide a
secondary review of applications. However, it is unclear whether the
composition of the advisory committee reflects the broad array of expertise and
stakeholder representation that the review of an HIV vaccine might require.
Like most citizens of the world, we hope that science will one day produce
an HIV vaccine that is similar to many other vaccines, with rates of efficacy
approaching one hundred percent. In the meantime, health policy makers will
do well to anticipate the opportunities and challenges that a moderately
effective HIV vaccine will present.

219. FDA Basic Video: Norman Baylor Discusses Vaccines, FOOD & DRUG ADMIN. (April
11, 2014), http://www.fda.gov/AboutFDA/Transparency/Basics/ucm195661.htm.

